IDD biotech aims to improve the life of patients by developing differentiated therapeutic MAbs for the pharmaceutical market with a pipeline of internally discovered product candidates and strategic collaborations with research institutes and pharmaceutical companies.
IDD Biotech – differentiated therapeutic MAbs
IDD Biotech is a Biopharma company dedicated in the creation and development of differentiated therapeutic antibodies for the treatment of cancer, infectious diseases, autoimmune diseases, central nervous system diseases. IDD Biotech uses its in-depth knowledge of antibody-biology to generate and select innovative and improved biopharmaceutical drugs. IDD Biotech develops three main MAb types : Fc optimized or not naked antibodies using its afucosylated MAb platform, Antibody-Drug-Conjugates (ADC) and multivalent antibodies.
IDD Biotech is building an innovative product candidate portfolio satisfying an unmet medical need or exhibiting advantages over current therapies. IDD Biotech‘s pipeline currently consists of 4 pre-clinical stage therapeutic MAbs and 4 active drug discovery programs.
IDD Biotech ‘s close ties with research institutes, biotechnology companies, enable to co-develop promising projects at an early stage. Then IDD Biotech partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market. Management Team is composed by Jean-Pierre LEHNER, Claudine VERMOT-DESROCHES and Hélène ROUQUETTE. IDD Biotech is headquartered in Lyon (France).
More about this biotech company : www.idd-biotech.com